• Webinar to be hosted on Thursday Sept. 22, 2022 at 12:00 p.m. ET, register here.
• Dr. Houghton will discuss challenges in drug development for pediatric cancers and preliminary results from Lantern’s drug candidates in preclinical pediatric cancer models with unmet clinical needs.

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR^® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that it will host a virtual key opinion leader (KOL) webinar on Sept. 22, 2022 at 12:00 p.m. ET. The webinar will focus on challenges in drug development for pediatric cancers and the potential of Lantern’s drug candidates LP-184 and LP-284 for several rare pediatric cancers.

The webcast will feature a leading expert in pediatric cancer research, Peter Houghton, Ph.D., Professor & Principal Investigator at Greehey Children's Cancer Research Institute (Greehey CCRI) at UT Health Science Center-San Antonio. During the webcast, Dr. Houghton will discuss the disparities and hurdles that currently exist in pediatric cancer research, drug development, and clinical trial design compared to adults. He will also provide details on exciting new preclinical results for LP-284 and its preclinical efficacy in vivo for several pediatric cancer models including Ewing’s sarcoma, malignant rhabdoid tumors, and alveolar rhabdomyosarcomas. Details on the webinar and how to register can be found below:

Virtual KOL Webinar Details:

• When: Thursday, September 22, 2022 at 12:00 p.m. ET
• Webinar Length: 20 minutes
• Registration, please use the link below:
  
  https://us06web.zoom.us/webinar/register/7916625619023/WN_RmePEGlpSviaLTsECKdaVA
• A replay of the webinar will be available on Lantern’s website beginning on September 23, 2022:
  
  www.lanternpharma.com

In early 2022, Lantern entered a research collaboration with Dr. Houghton to evaluate Lantern’s drug candidates LP-184 and LP-284 in several pediatric cancer models. Preliminary results from the initial phase of the LP-284 experiments have been obtained, with additional experiments planned for both LP-184 and LP-284 in the second half of 2022.

About Dr. Peter Houghton:

Dr. Houghton is an internationally recognized researcher in pediatric oncology and drug development. He received his Ph.D. in 1976 from the Institute of Cancer Research at the University of London, after which he spent over 30 years with St. Jude Children’s Research Hospital where he was the chair of Molecular Pharmacology and co-leader of the Solid Malignancies Research Program. Most recently, he served as the Director of the Greehey CCRI at UT Health Science Center-San Antonio from 2014 to 2021. At the Greehey CCRI, Dr. Houghton’s laboratory focuses on the development of novel approaches for the treatment of pediatric cancers, which has included creating of one of the most comprehensive patient-derived xenograft (PDX) model libraries for pediatric cancers. These PDX models are a critical resource to evaluate novel therapeutics in clinically relevant pediatric cancer models.

About the Greehey CCRI:

Since 2004, UT Health San Antonio, Greehey CCRI’s mission has been to advance scientific knowledge relevant to childhood cancer, contribute to understanding its causes, and accelerate the translation of knowledge into novel therapies. Greehey CCRI strives to have a national and global impact on childhood cancer by discovering, developing, and disseminating new scientific knowledge. More information on the Greehey CCRI can be found on their Website, Facebook, Twitter, LinkedIn, and Instagram.

About Lantern Pharma:

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage oncology-focused biopharmaceutical company leveraging its proprietary RADR^® A.I. and machine learning platform to discover biomarker signatures that identify patients most likely to respond to its pipeline of genomically targeted therapeutics. Lantern is currently developing four drug candidates and an ADC program across nine disclosed tumor targets, including two phase 2 programs. By targeting drugs to patients whose genomic profile identifies them as having the highest probability of benefiting from the drug, Lantern's approach represents the potential to deliver best-in-class outcomes.

Please find more information at:

Website: www.lanternpharma.com

LinkedIn: https://www.linkedin.com/company/lanternpharma/

Twitter: @lanternpharma

Lantern’s Investor Relations Contact:

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR^® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR^® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR^® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005207/en/